NCT05605509 2026-02-06
RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Canadian Cancer Trials Group
Institut du Cancer de Montpellier - Val d'Aurelle
Novartis
Hospices Civils de Lyon
Leap Therapeutics, Inc.
Federation Francophone de Cancerologie Digestive
Pierre Fabre Medicament